This is a non-randomized biomarker study with the aim to evaluate the relationship between APOBEC3B (A3B) expression in primary head and neck cancers (HNC), anus, and cervix tumors and pathologic response to definitive chemoradiation therapy.
Principal Investigator
Shraddha Dalwadi
Regulatory Point of Contact
Frances Crawford
210-450-5037
crawfordf1@uthscsa.edu
Regulatory Point of Contact
Myrna Montenegro
210-450-5954
montenegro@uthscsa.edu
Regulatory Point of Contact
Kathleen Rodriguez
210-450-1365
rodriguezk3@uthscsa.edu
Regulatory Point of Contact
Benjamin Schleif
210-450-1366
schleifb@uthscsa.edu
Regulatory Point of Contact
Morgan Seekatz
210-450-1133
seekatz@uthscsa.edu
• Patients must be at least 18 years of age.
• Patients must have a suspicion for head and neck cancer needing to undergo biopsy for diagnosis and ultimately definitive-intent chemoradiation
• Patients must have the ability to understand and the willingness to sign a written informed consent document.
Other Exclusion Criteria:
• Patients with distant metastatic disease as determined by the treating provider.
• Any other illness or condition that the treating investigator feels would interfere with study compliance or would compromise the patient’s safety or study endpoints/validity.